

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ORENITRAM™ safely and effectively. See Full Prescribing Information for ORENITRAM.

**ORENITRAM (treprostinil) Extended Release Tablets for oral administration**

Initial U.S. Approval: 2002

### INDICATIONS AND USAGE

Orenitram is a prostacyclin vasodilator indicated for:

- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (75%) or PAH associated with connective tissue disease (19%). (1.1)

As the sole vasodilator, the effect on exercise is small. Orenitram has not been shown to add to other vasodilator therapy. (1.1)

### DOSAGE AND ADMINISTRATION

- Give with food. Swallow tablets whole; use only intact tablets. (2.1)
- Starting dose: 0.25 mg BID. (2.1)
- Titrate by 0.25 mg or 0.5 mg BID or 0.125 mg TID, not more than every 3 to 4 days as tolerated. (2.1)
- Maximum dose is determined by tolerability. (2.1)
- Mild hepatic impairment (Child Pugh Class A): Initiate at 0.125 mg BID. Increment at 0.125 mg BID every 3 to 4 days. (2.1)
- Avoid use in patients with moderate hepatic impairment. (2.1)

### DOSAGE FORMS AND STRENGTHS

Extended Release Tablets: 0.125 mg, 0.25 mg, 1 mg and 2.5 mg. (3)

### CONTRAINDICATIONS

- Severe hepatic impairment (Child Pugh Class C). (4)

### WARNINGS AND PRECAUTIONS

- Do not abruptly discontinue dosing. (2.2, 5.1)
- Increased risk of bleeding, particularly in patients receiving anticoagulants. (5.2)
- Do not take Orenitram with alcohol (5.3)
- In patients with diverticulosis Orenitram tablets can become lodged in a diverticulum. (5.4)

### ADVERSE REACTIONS

Most common adverse reactions (incidence >10%) reported in clinical studies with Orenitram are headache, nausea, and diarrhea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact United Therapeutics Corp. at 1-866-458-6479 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### DRUG INTERACTIONS

- Blood pressure lowering drugs (e.g., diuretics, antihypertensive agents, or vasodilators): Risk of hypotension (7.1)
- When co-administered with strong CYP2C8 inhibitors the initial dose is 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days. (7.3)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 12/2013

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1. INDICATIONS AND USAGE

1.1 Pulmonary Arterial Hypertension

### 2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

2.2 Interruptions and Discontinuation

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

5.1 Worsening PAH Symptoms upon Abrupt Withdrawal

5.2 Risk of Bleeding

5.3 Increased Exposure with Alcohol

5.4 Use in Patients with Blind-end Pouches

### 6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

### 7 DRUG INTERACTIONS

7.1 Antihypertensive Agents or Other Vasodilators

7.2 Anticoagulants

7.3 Effect of CYP2C8 Inhibitors

### 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Labor and Delivery

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Patients with Hepatic Impairment

8.7 Patients with Renal Impairment

### 10 OVERDOSAGE

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

14.1 Clinical Trials in Pulmonary Arterial Hypertension (PAH)

### 16 HOW SUPPLIED / STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage

### 17 PATIENT COUNSELING INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed

## FULL PRESCRIBING INFORMATION

### 1. INDICATIONS AND USAGE

#### 1.1 Pulmonary Arterial Hypertension

Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (75%) or PAH associated with connective tissue disease (19%).

When used as the sole vasodilator, the effect of Orenitram on exercise is about 10% of the deficit, and the effect, if any, on a background of another vasodilator is probably less than this. Orenitram is probably most useful to replace subcutaneous, intravenous, or inhaled treprostinil, but this use has not been studied.

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 Recommended Dosing

Orenitram is supplied as extended release tablets. Individualize dosing of Orenitram according to clinical response.

The recommended starting dose of Orenitram is 0.25 mg twice daily (BID) with food, taken approximately 12 hours apart. Increase the dose as tolerated to achieve optimal clinical response. The recommended increment is 0.25 or 0.5 mg BID every 3-4 days. If 0.25 mg BID dose increments are not tolerated consider titrating slower. The total daily dose can be divided and given three times daily with food (TID; approximately 8 hours apart), titrating by increments of 0.125 mg TID.

The maximum dose is determined by tolerability. The mean dose in a controlled clinical trial at 12 weeks was 3.4 mg BID. Maximum doses studied were 12 mg BID in the 12-week blinded study and up to 21 mg BID in an open-label long-term study.

If intolerable pharmacologic effects occur, decrease the dose in increments of 0.25 mg. Avoid abrupt discontinuation [see *Warnings and Precautions* (5.1)].

**Hepatic impairment:** In patients with mild hepatic impairment (Child Pugh Class A) start at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days. Avoid use of Orenitram in patients with moderate hepatic impairment (Child Pugh Class B). Orenitram is contraindicated in patients with severe hepatic impairment (Child Pugh Class C) [see *Contraindications* (4), *Warnings and Precautions* (5.4), *Use in Specific Populations* (8.6), and *Clinical Pharmacology* (12.3)].

**Concomitant administration with CYP2C8 inhibitors:** When co-administered with strong CYP2C8 inhibitors (e.g., gemfibrozil) the initial dose is 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days.

Take Orenitram with food. Swallow Orenitram intact; use only intact tablets.

#### 2.2 Interruptions and Discontinuation

If a dose of medication is missed, take the missed dose as soon as possible, with food. If a patient misses two or more doses, restart at a lower dose and re-titrate.

In the event of a planned short-term treatment interruption for patients unable to take oral medications, consider a temporary infusion of subcutaneous or intravenous treprostinil. To calculate the total daily dose (mg) of treprostinil for the parenteral route divide the oral total daily dose by 5.

When discontinuing Orenitram, reduce the dose in steps of 0.5 to 1 mg per day [see *Warnings and Precautions (5.1)*].

### 3 DOSAGE FORMS AND STRENGTHS

Orenitram (treprostinil extended-release) is available in the following four strengths:

- 0.125 mg [White tablet imprinted with UT 0.125]
- 0.25 mg [Green tablet imprinted with UT 0.25]
- 1 mg [Yellow tablet imprinted with UT 1]
- 2.5 mg [Pink tablet imprinted with UT 2.5]

### 4 CONTRAINDICATIONS

Severe hepatic impairment (Child Pugh Class C) [see *Use In Specific Populations (8.6)* and *Clinical Pharmacology (12.3)*].

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Worsening PAH Symptoms upon Abrupt Withdrawal

Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.

#### 5.2 Risk of Bleeding

Orenitram inhibits platelet aggregation and increases the risk of bleeding.

#### 5.3 Increased Exposure with Alcohol

Do not take Orenitram with alcohol as release of treprostinil from the tablet may occur at a faster rate than intended.

#### 5.4 Use in Patients with Blind-end Pouches

The tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

### 6 ADVERSE REACTIONS

#### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In a 12-week placebo-controlled monotherapy study (Study 1; WHO Group 1; functional class II-III), the most commonly reported adverse reactions that occurred in patients receiving Orenitram included: headache, nausea, and diarrhea. Table 1 lists the adverse reactions that occurred at a rate on Orenitram at least 5% higher than on placebo.

Orenitram patients in Table 1 for Study 1 (N = 151) had access to 0.25 mg tablets at randomization. Approximately 91% of such patients experienced an adverse reaction, but only 4% discontinued therapy for an adverse reaction (compared to 3% receiving placebo). The overall discontinuation rate for any reason was 17% for active and 14% for placebo.

**Table 1: Adverse Reactions with Rates at Least 5% Higher on Orenitram Monotherapy than on Placebo**

Reaction	Orenitram N=151	Placebo N=77
Headache	63%	19%
Diarrhea	30%	16%
Nausea	30%	18%
Flushing	15%	6%
Pain in jaw	11%	4%
Pain in extremity	14%	8%
Hypokalemia	9%	3%
Abdominal discomfort	6%	0%

Orenitram was studied in a long-term, open-label extension study in which 824 patients were dosed for a mean duration of approximately 2 years. About 70% of patients continued treatment with Orenitram for at least a year. The mean dose was 4.2 mg BID at one year. The adverse reactions were similar to those observed in the placebo-controlled trials.

## **7 DRUG INTERACTIONS**

### **7.1 Antihypertensive Agents or Other Vasodilators**

Concomitant administration of Orenitram with diuretics, antihypertensive agents or other vasodilators increases the risk of symptomatic hypotension.

### **7.2 Anticoagulants**

Treprostinil inhibits platelet aggregation; there is increased risk of bleeding, particularly among patients receiving anticoagulants.

### **7.3 Effect of CYP2C8 Inhibitors**

Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil in healthy adult volunteers increases exposure to treprostinil. Reduce the starting dose of Orenitram to 0.125 mg BID and use 0.125 mg BID increments every 3 to 4 days [see *Dosage and Administration (2.1)* and *Clinical Pharmacology (12.3)*].

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

Pregnancy Category C.

Animal reproductive studies with treprostinil diolamine have shown an adverse effect on the fetus. There are no adequate and well-controlled studies in humans.

In rats, treatment with treprostinil diolamine had no effect on reproductive performance or sperm motility at doses up to 10 mg/kg/day. The exposures at this dose level are about 10- (male) to 18- (female) fold the usual human exposure at the mean dose of 3.4 mg BID.

In pregnant rats, reversible, dose-dependent decreases in body weight gain and food consumption were observed during the first four days of dosing in animals administered 10, 20 and 30 mg/kg/day treprostinil diolamine. In a dose range-finding study, there was a 17% decrease in the pregnancy rate in the animals administered 20 and 30 mg/kg/day. One dam in each of the 20 and 30 mg/kg/day had litters with no viable fetuses. In the definitive study (0, 5, 10 and 20 mg/kg/day), there were four treatment-related deaths, and a 32% decrease in the pregnancy rate for rats administered 20 mg/kg/day. There was an 8% decrease in the pregnancy rate in the animals administered 10 mg/kg/day. Across both studies, an increase in post-implantation loss was observed in animals administered 10 to 30 mg/kg/day, and a significant decrease in the mean number of live births was seen at dose levels  $\geq 10$  mg/kg/day. The no observed adverse effect level was 5 mg/kg/day (maternal, fetal viability and growth), and 20 mg/kg/day (teratogenicity), the highest dose tested in the definitive study. The exposures at 5 and 20 mg/kg/day doses represent 13 and 55 times, respectively, the human exposure.

For F<sub>1</sub> progeny, a decreased copulation index was observed at the 5 and 10 mg/kg/day treprostinil diolamine dose levels in rats. The no observed effect levels for physical development, reflex development, exploratory behavior, learning and memory, and sexual maturation was 10 mg/kg/day. The no observed effect level for F<sub>1</sub> progeny general development (based on body weight) was 10 mg/kg/day for females and  $\leq 2.5$  mg/kg/day for males; the no observed effect level for F<sub>1</sub> reproductive performance was 2.5 mg/kg/day or 6 times the human exposure.

In pregnant rabbits, the primary maternal adverse effects were gastrointestinal disturbance; dose-dependent decreases in mean body weight, body weight gain, and food consumption were observed. During the post-dose phase, the effect was reversed. In a dose range-finding study, there was a 17% decrease in the pregnancy rate for animals administered 4 mg/kg/day. A dose-dependent increase in post-implantation loss was observed. Two dams administered 4 mg/kg/day had litters with no viable fetuses; the mean fetal weight was slightly decreased in animals administered 4 mg/kg/day. In the definitive study, mean fetal weights were significantly decreased in animals administered 0.5 to 3 mg/kg/day of treprostinil diolamine. At doses of 1.5 and 3 mg/kg/day, external fetal and soft tissue malformations were observed in a few fetuses, and the total fetal skeletal malformations were significantly increased. The no observed adverse effect level was less than 0.5 mg/kg/day (maternal), 1.5 mg/kg/day (fetal viability and growth), and 0.5 mg/kg/day (teratogenicity). The 0.5 mg/kg/day dose represents about 5 times the human exposure.

## **8.2 Labor and Delivery**

The effect of Orenitram on labor and delivery in humans is unknown. No treprostinil treatment-related effects on labor and delivery were seen in animal studies.

## **8.3 Nursing Mothers**

It is not known whether treprostinil is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, choose Orenitram or breastfeeding.

## **8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

## **8.5 Geriatric Use**

Clinical studies of Orenitram did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.